"We have lost our way." A breast reconstruction surgeon recounts a potentially bankrupting dispute with UnitedHealthcare that began with her being interrupted during surgery to answer a phone call and justify the patient's need for an overnight hospital stay. ( NBC News )

The FDA expanded approval of the tocilizumab biosimilar (Avtozma) to include treatment of cytokine release syndrome in adults and children 2 years and older, Celltrion announced.

And the agency granted premarket approval to Instylla's Embrace hydrogel embolic system for treating hypervascular tumors in peripheral arteries, the company announced.

Faron Pharmaceuticals announced that a phase II trial of its investigational immunotherapy drug bexmarilimab plus standard-of-care azacitidine resulted in a 43% complet

See Full Page